<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00305903</url>
  </required_header>
  <id_info>
    <org_study_id>CENA713BUS32</org_study_id>
    <nct_id>NCT00305903</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease</brief_title>
  <official_title>A Prospective, 26-Week, Open-Label, Multi-Center, Single-Arm Pilot Study to Evaluate the Safety and Tolerability of Rivastigmine Capsule With Add on Memantine HCl in Patients With Probable Alzheimer's Disease (MMSE 10-20)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is a prospective, 26-week, open-label, single-arm multi-center pilot study. Eligible
      patients will receive open-label treatment with rivastigmine capsules plus memantine tablets
      as add on therapy. This study is designed to evaluate the safety and tolerability of add on
      therapy with memantine to rivastigmine capsules in patients with probable AD (MMSE 10-20)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of treatment with memantine and rivastigmine, measured by the incidence of GI adverse events (nausea and vomiting)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whether patients on rivastigmine and memantine are able to reach and maintain higher doses of rivastigmine compared to historical data of rivastigmine monotherapy</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Alzheimer's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine, memantine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of probable Alzheimer's disease;

          -  Have an MMSE score between 10 and 20;

          -  Must be able to swallow capsule/tablet;

          -  Must have a caregiver who is able to attend all study visits;

        Exclusion Criteria:

          -  Have an advanced, severe, progressive, or unstable disease of any type that may
             interfere with efficacy and safety assessments or put the patient at special risk;

          -  Have a current diagnosis of active, uncontrolled seizure disorder;

          -  Have a history within the past year or current diagnosis of cerebrovascular disease

          -  Have a current diagnosis of severe or unstable cardiovascular disease;

          -  Had a myocardial infarction (MI) within the last six months;

          -  Have specific respiratory, digestive, renal, or endocrine disorders;

          -  Have had previous treatment with rivastigmine or memantine;

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Chair</role>
    <affiliation>862-778-8300</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <state>New Jersey</state>
        <zip>08759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2006</study_first_submitted>
  <study_first_submitted_qc>March 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2006</study_first_posted>
  <last_update_submitted>December 17, 2007</last_update_submitted>
  <last_update_submitted_qc>December 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2007</last_update_posted>
  <keyword>Dementia,</keyword>
  <keyword>Alzheimer's,</keyword>
  <keyword>Rivastigmine,</keyword>
  <keyword>Memantine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
    <mesh_term>Rivastigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

